JP2000506723A5 - - Google Patents

Download PDF

Info

Publication number
JP2000506723A5
JP2000506723A5 JP1997529893A JP52989397A JP2000506723A5 JP 2000506723 A5 JP2000506723 A5 JP 2000506723A5 JP 1997529893 A JP1997529893 A JP 1997529893A JP 52989397 A JP52989397 A JP 52989397A JP 2000506723 A5 JP2000506723 A5 JP 2000506723A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1997529893A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000506723A (ja
JP4574750B2 (ja
Filing date
Publication date
Priority claimed from GBGB9603507.6A external-priority patent/GB9603507D0/en
Application filed filed Critical
Publication of JP2000506723A publication Critical patent/JP2000506723A/ja
Publication of JP2000506723A5 publication Critical patent/JP2000506723A5/ja
Application granted granted Critical
Publication of JP4574750B2 publication Critical patent/JP4574750B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP52989397A 1996-02-20 1997-02-20 抗体変異物 Expired - Lifetime JP4574750B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9603507.6 1996-02-20
GBGB9603507.6A GB9603507D0 (en) 1996-02-20 1996-02-20 Antibody variants
PCT/GB1997/000472 WO1997031024A1 (en) 1996-02-20 1997-02-20 Antibody variants

Publications (3)

Publication Number Publication Date
JP2000506723A JP2000506723A (ja) 2000-06-06
JP2000506723A5 true JP2000506723A5 (enExample) 2004-11-25
JP4574750B2 JP4574750B2 (ja) 2010-11-04

Family

ID=10789047

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52989397A Expired - Lifetime JP4574750B2 (ja) 1996-02-20 1997-02-20 抗体変異物

Country Status (11)

Country Link
US (2) US20020048578A1 (enExample)
EP (1) EP0970127B1 (enExample)
JP (1) JP4574750B2 (enExample)
AT (1) ATE373016T1 (enExample)
AU (1) AU723366B2 (enExample)
CA (1) CA2246715C (enExample)
DE (1) DE69738138T2 (enExample)
ES (1) ES2294793T3 (enExample)
GB (1) GB9603507D0 (enExample)
NZ (1) NZ331299A (enExample)
WO (1) WO1997031024A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE219517T1 (de) * 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
DE69938054T2 (de) 1998-11-18 2009-02-12 Genentech, Inc., South San Francisco Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
JP4334866B2 (ja) * 2000-10-09 2009-09-30 アイシス イノヴェイション リミテッド 治療用抗体
US20040109855A1 (en) * 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
EP1618891A1 (en) * 2003-03-31 2006-01-25 Kirin Beer Kabushiki Kaisha Method of inducing differentiation and proliferating regulatory t cell by anti-cd52 antibody and medicinal composition therefor
EP1756278B1 (en) * 2004-05-19 2008-09-17 MediGene Ltd. Method of improving t cell receptors
CA2601400A1 (en) * 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
CN101820898B (zh) * 2007-05-16 2013-10-30 中国抗体制药有限公司 互补决定区(CDRs)功能人源化
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
WO2010081173A2 (en) * 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
EP3683317A3 (en) 2009-05-13 2020-09-30 Genzyme Corporation Anti-human cd52 immunoglobulins
WO2010136598A1 (en) 2009-05-29 2010-12-02 Morphosys Ag A collection and methods for its use
HRP20181811T1 (hr) 2010-11-19 2018-12-28 Morphosys Ag Zbirka sljedova protutijela i njezina upotreba
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
WO2013152011A1 (en) * 2012-04-02 2013-10-10 Ab Biosciences, Inc. Novel human control antibodies and uses therefor
CN110078827A (zh) 2012-04-27 2019-08-02 西托姆克斯治疗公司 结合表皮生长因子受体的可活化的抗体其使用方法
KR20150139955A (ko) 2013-04-09 2015-12-14 보스톤 바이오메디칼, 인크. 암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2015089283A1 (en) 2013-12-11 2015-06-18 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
US20160120158A1 (en) * 2014-11-03 2016-05-05 The Johns Hopkins University Compositions and methods for the study and treatment of acute kidney injury
WO2016196935A1 (en) 2015-06-03 2016-12-08 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー, インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
EP3962926A4 (en) 2019-04-30 2022-11-23 Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center COMPOSITIONS AND METHODS FOR MODULATION OF ANTIBODY ACTIVITY

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
DE68909441T2 (de) * 1988-02-12 1994-02-10 British Tech Group Modifizierte Antikörper.
US5858725A (en) 1990-10-10 1999-01-12 Glaxo Wellcome Inc. Preparation of chimaeric antibodies using the recombinant PCR strategy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0610447B1 (en) * 1991-10-15 1998-12-16 Btg International Limited CDw52 - SPECIFIC ANTIBODY FOR TREATMENT OF T-CELL MEDIATED INFLAMMATION OF THE JOINTS
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method

Similar Documents

Publication Publication Date Title
JP2000503556A5 (enExample)
JP2000504599A5 (enExample)
JP2000504898A5 (enExample)
JP2000507816A5 (enExample)
JP2000505616A5 (enExample)
JP2000505324A5 (enExample)
JP2000506629A5 (enExample)
JP2000510722A5 (enExample)
JP2000507594A5 (enExample)
JP2000506111A5 (enExample)
JP2000502804A5 (enExample)
JP2000507671A5 (enExample)
JP2000504327A5 (enExample)
JP2000501338A5 (enExample)
JP2000506008A5 (enExample)
JP2000507722A5 (enExample)
JP2000505632A5 (enExample)
JP2000505352A5 (enExample)
JP2000503848A5 (enExample)
JP2000505830A5 (enExample)
JP2000507742A5 (enExample)
JP2000503413A5 (enExample)
JP2000505916A5 (enExample)
JP2001504765A5 (enExample)
JP2000504462A5 (enExample)